CNGB3-achromatopsia clinical trial with CNTF: Diminished rod pathway responses with no evidence of improvement in cone function

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 3, 2015, Pages 1505-

  Langlo, Christopher ^a   Dubis, Adam ^b,c   Michaelides, Michel ^b,c   Carroll, Joseph ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; CYCLIC NUCLEOTIDE GATED CHANNEL;

CNGB3 GENE; COLOR BLINDNESS; GENE; GENE MUTATION; HUMAN; LETTER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTORECEPTOR; PRIORITY JOURNAL; SCANNING LASER OPHTHALMOSCOPY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL SYSTEM FUNCTION; COLOR VISION DEFECTS; FEMALE; MALE; METABOLISM; PHYSIOLOGY; RETINA ROD;

CILIARY NEUROTROPHIC FACTOR; COLOR VISION DEFECTS; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; FEMALE; HUMANS; MALE; RETINAL ROD PHOTORECEPTOR CELLS;

EID: 84924255920     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15897     Document Type: Letter

References (4)

1. Zein WM, Jeffrey BG, Wiley HE, et al. CNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone function. Invest Ophthalmol Vis Sci. 2014;55:6301–6308.
2. Sundaram V, Wilde C, Aboshiha J, et al. Retinal structure and function in achromatopsia: implications for gene therapy. Ophthalmology. 2014;121:234–245.
3. Dubis AM, Cooper RF, Aboshiha J, et al. Genotype-dependent variability in residual cone structure in achromatopsia: toward developing metrics for assessing cone health. Invest Ophthalmol Vis Sci. 2014;55:7303–7311.
4. Scoles D, Sulai YN, Langlo CS, et al. In vivo imaging of human cone photoreceptor inner segments. Invest Ophthalmol Vis Sci. 2014;55:4244–4251.